Clidinium
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Clidinium: From Irritable Bowel Syndrome to Cauda Equina Syndrome
One-Sentence Summary
Clidinium is an antimuscarinic (anticholinergic) drug originally used for gastrointestinal disorders such as irritable bowel syndrome, gastroenteritis and enterocolitis. The TxGNN model predicts it may be effective for cauda equina syndrome (top-ranked prediction), but this prediction rests on the model alone, with 0 clinical trials and 0 publications supporting it. The better-supported alternative among the predictions is peptic ulcer disease, with 6 publications (mostly historical, combination-product reports).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Irritable bowel syndrome, gastroenteritis, enterocolitis (the registered Singapore product labels carry no indication text; these indications come from the knowledge graph) |
| Predicted New Indication | Cauda equina syndrome |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, clidinium is a quaternary anticholinergic that blocks muscarinic receptors and reduces smooth-muscle activity in the gut and other organs.
In theory, this could relate to the bladder and bowel dysfunction seen in cauda equina syndrome. However, the disease is a compressive neurological injury that needs surgical decompression, so an antimuscarinic could at most relieve symptoms as an adjunct. The prediction appears to reflect network proximity in the knowledge graph rather than a proven therapeutic mechanism.
Other predictions fall into three groups:
- Plausible mechanism, no data: obsolete neurogenic bladder. Blocking detrusor muscarinic receptors is an established approach, but no supporting bladder data exist for clidinium and better-studied alternatives are available.
- Upper-GI conditions with some literature: gastroduodenitis and peptic ulcer disease. The rationale is reduced gastric secretion and GI spasm, plus the anxiolytic effect of chlordiazepoxide in the fixed-dose combination (Librax).
- Weak or implausible links: the myasthenia-related predictions and the broad categories (autoimmune disease of the peripheral nervous system, disease of receptor activity). Myasthenia involves nicotinic receptor autoimmunity, whereas clidinium blocks muscarinic receptors.
Clinical Trial Evidence
Currently no related clinical trials are registered for the top predicted indication, cauda equina syndrome, or for any of the other nine predictions.
Literature Evidence
No literature is available for cauda equina syndrome. The table below shows the most relevant publications for peptic ulcer disease (rank 4), the best-documented alternative prediction. Most are historical, combination-product reports, and several have no abstract available.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27386057 | 2016 | Clinical study (design to be verified) | Caspian J Intern Med | Evaluated adding clidinium-C to 14-day PPI-based triple therapy for H. pylori eradication and its effect on drug side effects |
| 4892352 | 1969 | Clinical evaluation | Br J Clin Pract | Clidinium and Librax in duodenal ulcer management |
| 14497768 | 1962 | Clinical trial report | Minerva Med | Librax (clidinium plus chlordiazepoxide) in several digestive tract diseases |
| 14477958 | 1962 | Clinical report | Hospital (Rio de Janeiro) | Clidinium plus chlordiazepoxide in gastroduodenal peptic ulcer (preliminary note) |
| 14142206 | 1964 | Clinical report | Rev Clin Esp | Chlordiazepoxide plus clidinium in gastroduodenal ulcer |
| 28539 | 1978 | Animal study (mouse) | Pharmacology | Benzodiazepine plus anticholinergic (including clidinium) gave additive or supra-additive protection against stress-induced gastric erosion |
For large intestine disease (rank 10), one small physiological study is available:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 345122 | 1978 | Physiological/clinical study | N Engl J Med | In 10 IBS patients, clidinium was tested against the colonic response to a meal; it did not affect colonic slow-wave frequency |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN03049P | AA PHARMA CHLORAX CAPSULE | Capsule | Not stated in the available data |
| SIN08651P | CHLOBAX TABLET | Tablet, sugar coated | Not stated in the available data |
Both licences are valid single-ingredient registrations, and both products are oral.
Safety Considerations
- Contraindications flagged by the knowledge graph (not label text): hypertension, gastric ulcer, anxiety and other mental disorders (including psychotic and schizoaffective disorders), porphyria, kidney disease, liver disease, gallbladder disease, benign prostatic hyperplasia, coronary artery disease, sleep apnoea syndromes, angle-closure glaucoma, myasthenia gravis and other neuromuscular junction disease, and lung disease.
- Myasthenia gravis appears both as a contraindication and as a predicted indication, which makes the myasthenia-related predictions especially doubtful.
- Drug interactions: 100 interactions were recorded; those listed here are mostly moderate.
- Opioids and analgesics: fentanyl, alfentanil, codeine, dihydrocodeine, hydrocodone, tramadol
- Other anticholinergics and antimuscarinics: aclidinium, hyoscyamine, amitriptyline, amantadine
- Antihistamines: acrivastine, phenyltoloxamine
- Others: botulinum toxin type A, phenylephrine, acebutolol, acetylcholine, loperamide, ethanol
- Minor: acetaminophen, hydrochlorothiazide
- Package insert warnings and contraindications were not available. Please refer to the package insert for the full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction, cauda equina syndrome, has only a model score and no trials or publications. The disease needs surgical treatment, and the antimuscarinic mechanism could at most relieve symptoms. Among the other predictions, only peptic ulcer disease has a modest body of evidence (L4), and it is dated and combination-based. The contraindication and interaction burden is also substantial.
To proceed, the following is needed:
- The HSA package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- A check of the design and outcomes of the 2016 H. pylori study (PMID 27386057), to decide whether peptic ulcer disease merits a focused research question
- Clinical rationale for any bladder or neurological use, compared with established antimuscarinics such as oxybutynin or solifenacin
- Route and formulation compatibility checks for the chosen indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.